Investigational drug · Phase 2
CAN016
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Patients With Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CAN016"
First trial start
2026
Jun 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAN016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Patients With Advanced Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CAN016" as an intervention, largest first.
- CW-301 FIH Study of CAN016Recruiting
Canwell Biotech LimitedIndustry
NCT07664150 · 90 participants (planned) · Start Jun 18, 2026 · Primary completion Dec 30, 2028
Drug: CAN016; CAN016 · For: Patients With Advanced Solid Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Patients With Advanced Solid Tumors
- TCC1727Phase 22 trials
Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.